US 12,281,148 B2
Anti-pd-1 antibody-attenuated IL-2 immunoconjugates and uses thereof
David S. Wilson, Jr., Redwood City, CA (US); Kim Tran Yap, Atherton, CA (US); Paul Ayton, San Francisco, CA (US); Debasish Sen, Redwood City, CA (US); Julia Rozenfeld, Gordon (AU); Sachin Badrinath Surade, Macquarie Park (AU); and Anthony Gerard Doyle, Macquarie Park (AU)
Assigned to Cephalon LLC
Filed by Cephalon LLC, West Chester, PA (US)
Filed on Sep. 3, 2024, as Appl. No. 18/823,422.
Application 18/823,422 is a continuation of application No. 18/335,650, filed on Jun. 15, 2023.
Claims priority of provisional application 63/502,746, filed on May 17, 2023.
Claims priority of provisional application 63/481,630, filed on Jan. 26, 2023.
Claims priority of provisional application 63/352,842, filed on Jun. 16, 2022.
Prior Publication US 2024/0425562 A1, Dec. 26, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/55 (2006.01); C07K 16/28 (2006.01)
CPC C07K 14/55 (2013.01) [C07K 16/2818 (2013.01); C07K 2317/21 (2013.01); C07K 2317/75 (2013.01); C07K 2317/92 (2013.01); C07K 2319/33 (2013.01); C07K 2319/75 (2013.01)] 10 Claims
OG exemplary drawing
 
1. An anti-human PD-1 (hPD-1) antibody-modified human interleukin-2 (hIL-2) immunoconjugate comprising:
a modified hIL-2 protein comprising the amino acid sequence of SEQ ID NO: 217; and
an anti-hPD-1 antibody, or antigen-binding fragment thereof, that immunospecifically binds to hPD-1, wherein the antibody or antigen-binding fragment thereof, comprises a heavy chain complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 418, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 419, a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 420, a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 421, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 422, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 423.